For research use only. Not for therapeutic Use.
Lurbinectedin (Cat No.:I013699) is a novel anticancer agent that functions as a DNA minor groove binder. It exhibits potent anti-tumor activity by forming covalent adducts with DNA, resulting in DNA damage and inhibition of DNA transcription and replication. Lurbinectedin has shown efficacy against a variety of cancer types, including ovarian cancer, small-cell lung cancer, and soft-tissue sarcomas. It specifically targets cancer cells and has demonstrated selective cytotoxicity towards tumor cells while sparing normal cells. The compound’s ability to inhibit the growth of RMG1 and RMG2 cells with high potency highlights its potential as an effective anticancer therapy.
Catalog Number | I013699 |
CAS Number | 497871-47-3 |
Molecular Formula | C₄₁H₄₄N₄O₁₀S |
Purity | 98% |
Target | CYP3A4 |
Target Protein | |
Solubility | DMSO: 10 mM |
Appearance | Solid |
Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
IC50 | IC50: 1.25 nM (RMG1), 1.16 nM (RMG2) |
IUPAC Name | [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate |
InChI | InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1 |
InChIKey | YDDMIZRDDREKEP-HWTBNCOESA-N |
SMILES | CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O |
Reference | 1. Takahashi R, et al. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary. PLoS One. 2016 Mar 17;11(3):e0151050.<br /> |